- Home
- TR vs RARE Comparison
TR vs RARE Comparison
Compare TR & RARE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TR
- RARE
- Stock Information
- Founded
- TR 1896
- RARE 2010
- Country
- TR United States
- RARE United States
- Employees
- TR N/A
- RARE N/A
- Industry
- TR Specialty Foods
- RARE Biotechnology: Pharmaceutical Preparations
- Sector
- TR Consumer Staples
- RARE Health Care
- Exchange
- TR Nasdaq
- RARE Nasdaq
- Market Cap
- TR 2.9B
- RARE 2.6B
- IPO Year
- TR N/A
- RARE 2014
- Fundamental
- Price
- TR $38.66
- RARE $29.69
- Analyst Decision
- TR
- RARE Strong Buy
- Analyst Count
- TR 0
- RARE 14
- Target Price
- TR N/A
- RARE $86.64
- AVG Volume (30 Days)
- TR 184.2K
- RARE 2.1M
- Earning Date
- TR 07-24-2025
- RARE 08-05-2025
- Dividend Yield
- TR 0.94%
- RARE N/A
- EPS Growth
- TR N/A
- RARE N/A
- EPS
- TR 1.24
- RARE N/A
- Revenue
- TR $722,849,000.00
- RARE $610,159,000.00
- Revenue This Year
- TR N/A
- RARE $18.70
- Revenue Next Year
- TR N/A
- RARE $26.76
- P/E Ratio
- TR $31.16
- RARE N/A
- Revenue Growth
- TR N/A
- RARE 26.77
- 52 Week Low
- TR $27.14
- RARE $25.81
- 52 Week High
- TR $40.43
- RARE $60.37
- Technical
- Relative Strength Index (RSI)
- TR 55.04
- RARE 51.57
- Support Level
- TR $38.31
- RARE $27.00
- Resistance Level
- TR $40.03
- RARE $29.37
- Average True Range (ATR)
- TR 0.89
- RARE 1.12
- MACD
- TR -0.15
- RARE 0.52
- Stochastic Oscillator
- TR 47.83
- RARE 88.55
About TR Tootsie Roll Industries Inc.
Tootsie Roll Industries Inc manufactures and sells confectionery products. Notable varieties include Tootsie Roll and Tootsie Pops, Charms, Blow-Pops, Dots, Junior Mints, Sugar Daddy and Sugar Babies, Andes, Dubble Bubble, Razzles among others. The company sells its products to wholesale distributors and directly to retail stores. Geographically, it generates a majority of its revenue from the United States and rest from Canada, Mexico and other regions.
About RARE Ultragenyx Pharmaceutical Inc.
Ultragenyx Pharmaceutical Inc is a USA-based biopharmaceutical company. It identifies, acquires, develops, and commercializes novel products for the treatment of serious rare and ultra-rare diseases, with a focus on serious, debilitating genetic diseases. The company's medicine portfolio includes Crysvita, Dojolvi and Mepsevii. Crysvita is indicated for the treatment of X-linked hypophosphatemia (XLH) in adult and pediatric patients 1 year of age and older. Mepsevii is indicated in pediatric and adult patients for the treatment of Mucopolysaccharidosis VII.